Drug use evaluation in pregnant women attending antenatal care in Shashemene Referral Hospital, Oromia Regional State, Ethiopia

Gudeta Duga Geresu1, Dirirsa Tashome Sondesa1, Tadele Mekuriya Yadesa1✉, Andrew G Mtewa2 and Bontu Aschale Abebe3

Abstract

Objectives: The main aim of this study was to estimate relative proportions of medication use according to different pregnancy risk categories (A, B, C, D, X) among pregnant women attending antenatal care (ANC) visits at Shashemene Referral Hospital.

Methods: A hospital-based retrospective cross-sectional study was conducted at Shashemene referral hospital from February 2016 to February 2017. Structured data collection form was used to capture data from patient medication cards. SPSS version 16.0 was used to analyze the results after entering and importing from MS-Excel.

Results: A total of 317 pregnant women cards were collected and assessed during the study period in May, 2017. Most, 208(65.6%), of the pregnant women were in their second trimester of pregnancy followed by third trimester, 78(24.6%). Tetanus prevention in pregnancy, 274(86.4%), was the most common reason for drug use. Number of medications prescribed was highest, 384(68.2%), in second trimester followed by third trimester, 130(23.1%). More than half, 305(54.2%), of the drugs prescribed were under category C, tetanus toxoid (TT) vaccine alone accounting for 274 (89.8%) of them, followed by 36.8% from category A.

Conclusion: Vaccines, vitamins and minerals were the most frequently prescribed medications. The overall drug use condition during pregnancy in this study was inappropriate as more than half of the prescribed medications were from category C. On the other hand, category X medications were not prescribed.

Keywords
Drug use, pregnant women, Shashemene, Ethiopia

Date received: 18 March 2020; accepted: 27 August 2020

Background

Physiological changes during pregnancy quite often require the need for drug therapy which is not always safe. Among the most notorious examples is Thalidomide use for anxiety, insomnia and as an anti-emetic, and the use of which resulted in phocomelia and other congenital anomalies in thousands of children exposed in utero.1 Among the crucial outcomes of Evaluation of drug use during pregnancy include the following: the potential risk of harmful effects to fetus, physiological changes resulting in pharmacokinetic and pharmacodynamics changes, and the high drug-utilization patterns during pregnancy.2

The use of medications among expecting mothers has often been associated with significant problems in ANC due to the potential fetal risk associated with the use. According to drug utilization studies, the prevalence of drug use during pregnancy is high, varying from 44% to 99% in different areas across the world. In the treatment process of common complaints during pregnancy, a huge fraction of unnecessary

1Department of Pharmacy, Ambo University, Ambo, Ethiopia
2Department of Chemistry, Malawi University of Science and Technology, Thyolo, Malawi
3Department of Midwifery, Ambo University, Ambo, Ethiopia

Corresponding author:
Tadele Mekuriya Yadesa, Department of Pharmacy, Ambo University, P.O. Box 19, Ambo, Ethiopia.
Email: maatiikoo4@gmail.com
use of drugs has been extensively recounted in most developing countries. In line with endeavors to promote safe use of medications during pregnancy, the US Food and Drugs Administration (FDA) categorized drugs into five pregnancy risk categories: A, B, C, D, and X; among these groups, D and X medications are those with available evidence of significant harm in pregnancy. Category-A drugs are those with no risk to the fetus from well-controlled human studies. For drugs in category B, no evidence of risk from animal studies has been documented, but there are no controlled studies in pregnant women. Category C drugs are those associated with harm to fetus in animal studies but no adequate and well-controlled studies in pregnant women. For category D drugs, there is well-documented human fetal risk, and these should be generally avoided except occasional use when the maternal benefit outweighs the fetal risk. However, drugs with classification X are associated with prominent fetal harm and are contraindicated in pregnancy. Despite limited information on its safety, drug use in pregnancy is common. Supplementary drug treatment like iron, folic acid, calcium, and vitamins are prescribed commonly to improve overall nutritional status of mother and fetus. In addition, drugs may also be used for acute conditions not related to pregnancy or pre-existing chronic conditions such as diabetes, hypertension or epilepsy or to treat pregnancy-related disorders such as pregnancy induced hypertension and gestational diabetes. Therefore, adequate knowledge and more sensible prescription of drugs are crucial among pregnant women. Currently, drug use evaluation studies mainly involve assessing disease prevalence, drug consumption, rational use of drugs and adherence to evidence-based guidelines. The primary objective of a drug use evaluation study is to promote safe and effective use of medicines. Accordingly, such studies can potentially contribute in suggesting the right strategies and ways to improve prescribing practices. An international investigation sponsored by the World Health Organization (WHO) showed that pregnant women take an average of three prescribed drugs during pregnancy. Approximately 2%-5% of all live births are associated with congenital birth defects and about 1%-3% of all live births with a congenital defect are attributed to medication use by the mothers during pregnancy. During pregnancy, unnecessary use of drugs has been commonly identified in many developing countries. Self-medication is widely practiced by pregnant women to manage minor pregnancy-related conditions such as back pain, headache, heartburn, nausea, and vomiting. In these countries, the prevalence of drug use during pregnancy and their pregnancy risk categorization has been largely overlooked. However, studies from developed countries have indicated importance of ensuring rational prescribing during pregnancy. Because of the limited knowledge and inconsistencies about the use of drugs during pregnancy, the extensive drug use by pregnant women is an important public health issue. The main aim of this study was to estimate proportions of medication use from different pregnancy risk categories (A, B, C, D, and X) among pregnant women attending ANC visits at Shashemene Referral Hospital.

**Methods**

**Study area**

This study was retrospectively conducted from February, 2016 to February, 2017 at Shashemene Referral Hospital (SRH), which is found in Kuyera town. It is one of the oldest hospitals of the region; currently serving an estimated 1.2 million people. Geographically, it is located in Kuyera town about 238 km south of the capital city of Addis Ababa. All of the pregnant women in the catchment of the hospital were encouraged by the local health department to have four regular visits during each ANC cycle and all ANC services are completely free of charge in an attempt to improve access by those with low income or women with little awareness about the services. Additional visits were also advised if any complaint is felt by the clients amid the regular follow-up visits. Data were collected from 15 to 30 May 2017.

**Study design**

A retrospective cross-sectional study design was employed for drug use evaluation of pregnant women attending ANC at SRH.

**Study populations**

All patient cards of pregnant women who visited SRH, attended ANC and used at least one drug were included as the target population in this study.

**Eligibility criteria**

Eligible patient cards included those belonging to women who had been already enrolled in ANC program in the hospital and those who were prescribed with at least one medication during the follow-up visits under the current ANC cycle. Patient cards with incomplete or illegible medication charts with lacking the required drug information were excluded.

**Sample size determination and sampling technique**

**Sample size determination**

Sample size was calculated using formula for a single population proportion. Since there were no previous studies on the proportion of medication used from each of the different pregnancy risk categories (A, B, C, D or X), the estimate of maximum sample size was calculated from 50% proportion at 95% confidence level and 5% tolerable margin of error.
The finite population was 1800 patient cards of pregnant women attending antenatal care (ANCs) in SRH all of which were potential participants.

Since the study population was less than 10,000, the final sample size \(n_f\) was calculated by correction formula for finite population as follows

\[
n_f = \frac{n}{1 + \frac{n}{N}}
\]

where \(N\) is the original sample size, \(n\) is the final sample size, \(Z\) is the standard normal value at CI of 95% which is 1.96, \(P\) is the estimate of prevalence rate, and \(D\) is the margin of error.

Therefore, \(n_f = \frac{(384\,*\,1800)}{(384\,\,+\,\,1800)} = 317\) medication cards of pregnant women following ANC were taken as a final sample size.

**Sampling technique**

Systematic random sampling technique was used as follows by first numbering patient cards in ascending order from 1 to 1800 using the patient card numbers assigned by the hospital during first enrolment to the hospital.

Second, sampling interval, \(K\), was determined

\[
K = \frac{(Total\,\,population)}{(Determined\,\,size)} = \frac{1800}{317} \approx 5
\]

Then, from 1, 2, 3, 4 and 5, number 5 was chosen using random number method; thus, starting with 5 every fifth patient card was included; 5, 10, 15, 20 . . . until the target sample size of 317 was reached.

**Study variables**

**Independent variables**

- Age
- Trimester of pregnancy
- Duration on ANC
- The prescriber’s knowledge and experience
- Drug information service

**Dependent variables**

- Drug use
- Potential teratogenicity

**Data collection and analysis**

**Data collection**

Data on age of participant, medications given and gestational age were collected using a structured data collection form which was used to extract pertinent information from patient medication files (Supplemental Material).

**Statistical analysis**

The collected data were sorted and classified in accordance to US FDA risk classification for pregnancy and analyzed using SPSS version 16.0.

**Data quality control**

The data collectors were trained on the use of the data collection tool and on how to review the patient cards before the data collection started. The collected data were checked for its completeness, accuracy, and clarity daily by principal investigator.

**Results**

**Participants’ data**

The medication cards of a total of 317 pregnant women were studied during the study period. More than half, 178(56.2%), of the subjects were under 15–24 age group followed by 25–34 years, 126 (39.7%). Most, 208 (65.6%), of the pregnant women were in their second trimester of pregnancy followed by third trimester, 78(24.6%; Table 1).

**Reasons for drug use in pregnant women**

Tetanus prevention in pregnancy, 274(86.4%), was the most common reason for drug use followed by prevention of anemia, vitamin deficiency and the treatment of anemia 212(66.9%). Genitourinary infections accounted for 23 (7.3%), whereas pain killer, de-worming and respiratory infection accounted for 19 (5.9%), 15 (4.7%) and 7 (2.2%), respectively (Table 2).

**Drugs used and trimester of pregnancy**

The number of medications used was highest, 384(68.2%), in second trimester followed by third trimester 130(23.1%). Vaccines were the most commonly used drugs, 274 (48.7%), followed by minerals and vitamins, 212 (37.6%; Table 3).

**FDA risk category of drugs used in pregnant women**

More than half, 305(54.2%), of the drugs used by pregnant women were under category C; tetanus toxoid (TT) vaccine
accounting for 274 (89.8%). Among these, nearly three fourth, 215 (70.5%), were used during second trimester. Category A drugs, 207 (36.8%), were the second most commonly used drugs followed by category B, 50 (8.9%). No drug under category X was given to pregnant women in this study (Table 4).

Discussion

According to this study, the majority (56.2%) of pregnant women were in the age group of 15–24 years followed by 25–34 years. In this study, TT vaccination was the most frequently used (48.7%) medication during pregnancy followed by Iron/folic acid (37.6%), Antibiotics (5.9%) and Analgesics (3.4%). The use of antibiotics by only 5.9% women was much lower compared to a study from India\(^{16}\) in which metronidazole was used by 26.8% and ceftriaxone by 19.4%; as well as study done in Jazan, Saudi Arabia where the use of antibiotics was 19.9%. This variation is probably because the later was conducted at inpatient setting. However, the high rate of use of Iron/Folic acid (69.9%) in the current study is comparable to that of a study conducted on expecting mothers in Jazan, Saudi Arabia in which Iron/Folic acid was used by 82.9%.\(^{17}\) The significant use of antibiotics for treatment of urinary tract infections (7.3%) is comparable to a study conducted in the Brazil where most of the antibiotics used were to treat urinary tract infection (UTI).\(^{18}\)
In this study, majority of drugs were from category C (54.2%), followed by category A (36.8%), category B (8.9%) and D (0.33%). The proportion of using category A medications in this study (36.8%) was much higher than the other similar studies; 15.4% from Rajahmundry\textsuperscript{19} and 14.0% from Brazil.\textsuperscript{18} This can be attributed to the higher rate of iron/folic acid use during ANC as compared to the other studies. On the contrary, the proportion of using category B medications of 8.9% is comparable to 9.1% from a study Rajahmundry\textsuperscript{19} but much lower than 37.2% from the study in Brazil\textsuperscript{18} as well as 26.3% from a study in Jimma, Ethiopia.\textsuperscript{5} This difference might be due to more stringent adherence to Standard Treatment Guidelines (STG) among prescribers in the latter ones.

The proportion of using category C medications was comparable to the proportion of 53.1% from a study done on pregnant women in GSL Medical College and General Hospital, Rajahmundry.\textsuperscript{19} On the other hand, the proportion of using category C medications was significantly higher than 39.5% from a study in Brazil\textsuperscript{18} probably because of lower previous TT vaccinations in the current study, leading to the higher proportion of the use of TT during pregnancy, accounting for 274 (89.8%) of all category C medications, and a possibly more sophisticated health care system, including a more coordinated health care teams and availability of safer medications, in Brazil, a middle-income county. The occurrence of contraindicated medicines was desirably low.

Similar to a study from Brazil\textsuperscript{18} and another study from India,\textsuperscript{1} no woman was prescribed Category X drug during the current study. This was also comparable to the findings from other studies including Ethiopia,\textsuperscript{20} Netherland\textsuperscript{21} and Finland.\textsuperscript{22}

Limitations of the study
The important limitations encountered during the current study included unavailability of gestational age for some patients, incomplete recording of medications prescribed from other facilities, and the gap in identifying over-the-counter use of conventional as well as herbal medications used by the patients as patient files were the sole sources of the medications used.

Conclusion and recommendations

Conclusion
The overall drug use during pregnancy in this study was significantly inappropriate and irrational showing inconsistencies in adhering to STG. Excluding vaccinations, minerals and vitamins were the highest drugs used followed by antibiotics and analgesic drugs. Majority of the drug used were FDA category C, followed by category A and category B. None of the drugs were used from category X which have potential fatal harm to the fetus.

Recommendations
We recommended that there should be intensive assessment of pregnant women depending on the FDA risk category, gestational period or trimester and the risk benefit balance of a drug before it is prescribed. Drug information center in SRH should play great role in promoting rational drug use for pregnant women in line with national STG. In addition, the hospital pharmacist should work with other health professionals’ team to develop, implement, and deliver drug information and monitor a therapeutic plan to achieve optimal care for all pregnant women.

Acknowledgements
Authors acknowledge the management of Shashemene Referral Hospital and Ambo University for the support they offered for this work to be a success.
Author contributions
D.T.S. conceptualized and conducted the research; T.M.Y. conceptualized and conducted the research, supervised the study worked on the technicalities of the manuscript and edited the work; G.D.G. assisted with data collection and editing of this manuscript; A.G.M. worked on technical write up of the manuscript and editing; and B.A.A. supervised the technicalities of the research.

Consent for publication
All authors agree to the publication of this manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval and consent to participate
Ethical approval and clearance for the study was obtained from Ethical Review Board of Ambo University. Later, permission to conduct the study was granted from the hospital’s clinical administrator and the head of Gynecology and Obstetrics department. All of the individual patient’s information and the respective prescriber’s identity were kept confidential.

Availibility of data and material
All original data and materials for this research are available and will be produced upon request only where such an action does not breach ethical requirements.

References
1. Joshi H, Patel S, Patel K, et al. Drug use pattern during pregnancy: a prospective study at Tertiary Care Teaching Hospital. NHL J Med Sci 2012; 1(1): 14–17.
2. Gaidhankar SL, Pore SM, Deokate MN, et al. A study of drug utilization in indoor patients of high-risk pregnancy in a tertiary care hospital. Int J Basic Clin Pharmacol 2016; 5: 1366–1371.
3. Mohammed MA, Ahmed JH, Bushra AW, et al. Medications use among pregnant women in Ethiopia: a cross sectional study. J App Pharm Sci 2013; 3(4): 116–123.
4. Yahaya J, Yalwa T, Muhammad S, et al. Assessment of drugs use among pregnant women attending ANC in Sir Yahaya Memorial Hospital Birnin-Kebbi Kebbi State, Nigeria. J Health Med Nars 2016; 26: 169–182.
5. Fikadu M, Kebebe D, Amelo W, et al. Drug utilization pattern and potential teratogenicity risk among pregnant women visiting antenatal clinic: the case of a primary hospital. Indian J Pharm Prac 2015; 8(1): 27–33.
6. Inamdar IF, Aswar NR, Sonkar VK, et al. Drug utilization pattern during pregnancy. Indian Med Gazette 2012; 145: 305–311.
7. Gawde SR, Bhide SS, Patil TC, et al. Drug prescription pattern in pregnant women attending antenatal out patient department of a Tertiary Care Hospital. Br J Pharm Res 2013; 3(1): 1–12.
8. WHO International Working Group for Drug Statistics Methodology. Introduction to drug utilization research. Oslo: WHO, 2003, http://www.whocc.no/filearchive/publications/drug_utilization_research.pdf
9. Eze UI, Eferakeya AE, Oparah AC, et al. Assessment of prescription profile of pregnant women visiting antenatal Clinics. Pharm Pract 2007; 5(3): 135–139.
10. Misri S and Kendrick K. Treatment of perinatal mood and anxiety disorders: a review. Can J Psychiat 2007; 52(8): 489–498.
11. Bamboyee EA, Amorant OE and Yusu FB. Self-medication practices among workers in a tertiary hospital in Nigeria. Afr J Med Med Sci 2006; 35(4): 411–415.
12. Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001; 358(9290): 1287–1288.
13. Yusuff KB and Omaru-Osehe LD. Determinants of self medication practices among pregnant women in Ibadan. Nigeria. Int J Clin Pharm 2011; 33(5): 868–875.
14. Hardon A, Hodgkin C and Fresle D. How to investigate the use of medicines by consumers. Geneva: World Health Organization, 2004.
15. Gebremichael LG and Gomathi P. Assessment of drug use and effect in pregnant women attending antenatal care in Hospitals of Mekelle, Tigray, Ethiopia. J Drug Deliv Ther 2014; 4(6): 75–82.
16. Thomas JE, Paul EP, Geethu C, et al. Assessment of drug use pattern and WHO prescribing indicators in the department of obstetrics and gynecology prospectively. Int J Pharmacognosy Phytochem Res 2016; 6(4): 378–385.
17. Agarwal M, Nayee M, Safhi MM, et al. Prescribing pattern of drugs in the department of obstetrics and gynecology in expecting mothers in Jazan Region, KSA. Int J Pharm Pharm Sci 2014; 6(1): 658–661.
18. Araújo DD, Leal MM, Santos EJV, et al. Consumption of medicines in high-risk pregnancy: evaluation of determinants related to the use of prescription drugs and self-medication. Braz J Pharm Sci 2013; 49(3): 491–499.
19. Kumar MK, Raj VCR, Reddy LE, et al. Prescribing pattern in pregnant women in a tertiary care teaching hospital. Indo Am J Pharm Res 2015; 5(4): 3058–3062.
20. Etefa K and Kahissay MH. Assessment of drug prescribing pattern among pregnant women attending antenatal care in health centers found in Arada Subcity, Addis Ababa, Ethiopia. J Pharm Sci Bioscientific Res 2015; 5(4): 347–362.
21. Bakker MK, Jentink J, Vroom F, et al. Drug prescription pattern before, during and after pregnancy for chronic, occasional and pregnancy related drugs in the Netherlands. Br J Obstet Gynecol 2006; 113(5): 559–568.
22. Malm H, Martikainen J, Kalukka T, et al. Prescription of hazardous during pregnancy. Drug Saf 2004; 27: 899–908.
### Supplementary material

#### Data Collection Form

**Age (Years)**
- a. 15-24
- b. 25-34
- c. 35-44
- d. >=45

| Gestational age (weeks) | Trimester | Indication | Drug name | Dosage form | Route of administration | Drug class | Brand name | US FDA risk category |
|-------------------------|-----------|------------|-----------|-------------|-------------------------|------------|------------|---------------------|